Alligator Bioscience AB - Asset Resilience Ratio

Latest as of December 2025: 56.24%

Alligator Bioscience AB (ATORX) has an Asset Resilience Ratio of 56.24% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read ATORX current and long-term liabilities for a breakdown of total debt and financial obligations.

Liquid Assets

Skr62.20 Million
≈ $6.69 Million USD Cash + Short-term Investments

Total Assets

Skr110.60 Million
≈ $11.90 Million USD All company assets

Resilience Assessment

Very High
Financial Resilience Level

Asset Resilience Ratio Trend (2007–2025)

This chart shows how Alligator Bioscience AB's Asset Resilience Ratio has changed over time. See net assets of Alligator Bioscience AB for net asset value and shareholders' equity analysis.

Liquid Assets Composition Over Time

This chart breaks down Alligator Bioscience AB's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see market cap of Alligator Bioscience AB.

Current Liquid Assets Breakdown

Component Amount % of Total Assets
Cash & Equivalents Skr62.20 Million 56.24%
Short-term Investments Skr0.00 0%
Total Liquid Assets Skr62.20 Million 56.24%

Asset Resilience Insights

  • Very High Liquidity: Alligator Bioscience AB maintains exceptional liquid asset reserves at 56.24% of total assets.
  • This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
  • The company primarily holds liquidity in cash and equivalents rather than short-term investments.

Alligator Bioscience AB Industry Peers by Asset Resilience Ratio

Compare Alligator Bioscience AB's asset resilience ratio with other companies in the same industry.

Company Industry Asset Resilience Ratio
Argen-X
F:1AE
Biotechnology 25.67%
Tubize-Fin
BR:TUB
Biotechnology 0.05%
BrightGene Bio Medical Technology C
SHG:688166
Biotechnology 1.00%
Dashenlin Pharm Grp Co Ltd
SHG:603233
Biotechnology 0.02%
Staidson Beijing Biopharma
SHE:300204
Biotechnology 7.93%
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
Biotechnology 41.25%
Ardelyx Inc
NASDAQ:ARDX
Biotechnology 41.14%
Xiangxue Pharmaceutical
SHE:300147
Biotechnology 0.05%

Annual Asset Resilience Ratio for Alligator Bioscience AB (2007–2025)

The table below shows the annual Asset Resilience Ratio data for Alligator Bioscience AB.

Year Asset Resilience Ratio (%) Liquid Assets Total Assets Change
2025-12-31 56.24% Skr62.20 Million
≈ $6.69 Million
Skr110.60 Million
≈ $11.90 Million
-5.40pp
2024-12-31 61.64% Skr64.31 Million
≈ $6.92 Million
Skr104.34 Million
≈ $11.23 Million
+5.82pp
2023-12-31 55.82% Skr66.12 Million
≈ $7.12 Million
Skr118.45 Million
≈ $12.75 Million
-1.56pp
2022-12-31 57.38% Skr97.31 Million
≈ $10.47 Million
Skr169.58 Million
≈ $18.25 Million
-26.10pp
2021-12-31 83.48% Skr278.15 Million
≈ $29.93 Million
Skr333.20 Million
≈ $35.86 Million
+15.46pp
2020-12-31 68.02% Skr103.34 Million
≈ $11.12 Million
Skr151.94 Million
≈ $16.35 Million
-28.36pp
2019-12-31 96.38% Skr299.85 Million
≈ $32.27 Million
Skr311.13 Million
≈ $33.48 Million
+20.98pp
2018-12-31 75.40% Skr383.13 Million
≈ $41.23 Million
Skr508.16 Million
≈ $54.69 Million
+1.85pp
2017-12-31 73.55% Skr472.92 Million
≈ $50.89 Million
Skr643.03 Million
≈ $69.20 Million
-20.51pp
2016-12-31 94.06% Skr659.14 Million
≈ $70.93 Million
Skr700.78 Million
≈ $75.42 Million
+94.06pp
2015-12-31 0.00% Skr1.00K
≈ $107.62
Skr416.26 Million
≈ $44.80 Million
-51.18pp
2008-12-31 51.18% Skr10.00 Million
≈ $1.08 Million
Skr19.54 Million
≈ $2.10 Million
-29.54pp
2007-12-31 80.72% Skr38.62 Million
≈ $4.16 Million
Skr47.85 Million
≈ $5.15 Million
--
pp = percentage points

About Alligator Bioscience AB

ST:ATORX Sweden Biotechnology
Market Cap
$14.33 Million
Skr133.16 Million SEK
Market Cap Rank
#25969 Global
#546 in Sweden
Share Price
Skr0.21
Change (1 day)
-2.75%
52-Week Range
Skr0.16 - Skr7.20
All Time High
Skr55.78
About

Alligator Bioscience AB (publ), a research-based biotechnology company, develops antibody-based pharmaceuticals for cancer treatment in Finland and Sweden. The company develops Mitazalimab, a stimulatory antibody that targets CD40, which is in phase 2 clinical trial for the treatment of solid metastatic tumors, including pancreatic cancer; and ATOR-4066, tumor-directed bispecific antibody, develo… Read more